Acute exacerbations of idiopathic pulmonary fibrosis
…, DA Lynch, J Müller-Quernheim… - American journal of …, 2007 - atsjournals.org
The natural history of idiopathic pulmonary fibrosis (IPF) has been characterized as a steady,
predictable decline in lung function over time. Recent evidence suggests that some …
predictable decline in lung function over time. Recent evidence suggests that some …
[HTML][HTML] Oxidative stress in the pathogenesis of diffuse lung diseases: a review
…, C Olivieri, D Bennett, A Prasse, J Muller-Quernheim… - Respiratory …, 2009 - Elsevier
Oxidative stress is an imbalance between oxidants (reactive oxygen and nitrogen species)
and antioxidants that may affect lipids, DNA, carbohydrates and proteins. The lung is …
and antioxidants that may affect lipids, DNA, carbohydrates and proteins. The lung is …
Sarcoidosis: immunopathogenetic concepts and their clinical application
J Muller-Quernheim - European Respiratory Journal, 1998 - Eur Respiratory Soc
Our understanding of the immunopathogenesis of sarcoidosis has been advanced by studies
of bronchoalveolar lavage cells. Activated macrophages and T-cells have been identified …
of bronchoalveolar lavage cells. Activated macrophages and T-cells have been identified …
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
…, GJ Roth, F Hilberg, J Müller-Quernheim… - European …, 2007 - Eur Respiratory Soc
BIBF 1000 is a small molecule inhibitor targeting the receptor kinases of platelet-derived
growth factor (PDGF), basic fibroblast growth factor and vascular endothelial growth factor, …
growth factor (PDGF), basic fibroblast growth factor and vascular endothelial growth factor, …
A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18
…, E Vollmer, J Müller-Quernheim… - American journal of …, 2006 - atsjournals.org
… Ziegenhagen MW, Zabel P, Zissel G, Schlaak M, Müller-Quernheim J. Serum level of
interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am …
interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am …
Alternatively activated alveolar macrophages in pulmonary fibrosis—mediator production and intracellular signal transduction
…, W Luttmann, K Friedrich, J Müller-Quernheim… - Clinical …, 2010 - Elsevier
Activated macrophages have been characterized as M1 and M2 according to their inflammatory
response pattern. Here we analyzed the M2 marker expression and intracellular signal …
response pattern. Here we analyzed the M2 marker expression and intracellular signal …
Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis
…, P Rottoli, J Müller-Quernheim - American journal of …, 2009 - atsjournals.org
… Ziegenhagen MW, Zabel P, Zissel G, Schlaak M, Müller-Quernheim J. Serum level of
interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am …
interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity. Am …
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement
…, JF Donohue, J Müller-Quernheim… - American journal of …, 2006 - atsjournals.org
Rationale: Evidence suggests that tumor necrosis factor (TNF)-α plays an important role in
the pathophysiology of sarcoidosis. Objectives: To assess the efficacy of infliximab in …
the pathophysiology of sarcoidosis. Objectives: To assess the efficacy of infliximab in …
Sarcoidosis is associated with a truncating splice site mutation in BTNL2
…, M Platzer, M Krawczak, J Müller-Quernheim… - Nature …, 2005 - nature.com
Sarcoidosis is a polygenic immune disorder with predominant manifestation in the lung.
Genome-wide linkage analysis previously indicated that the extended major histocompatibility …
Genome-wide linkage analysis previously indicated that the extended major histocompatibility …
Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen
J Muller-Quernheim, K Kienast, M Held… - European …, 1999 - Eur Respiratory Soc
In a few patients with chronic sarcoidosis, prolonged, unacceptably high doses of corticosteroids
are required to achieve symptomatic relief. In these cases, a corticosteroid-sparing drug …
are required to achieve symptomatic relief. In these cases, a corticosteroid-sparing drug …